Contact the Editorial Desk

Editorial correspondence

Peptides Long Island welcomes correspondence on the research record: a citation quoted inaccurately, a trial that has published new results, a regulatory update, or a peer-reviewed study on MOTS-c, retatrutide, or semaglutide that should be added to the references page. This class of correction is the most useful message this guide receives.

The most actionable submissions specify the page in question, the exact passage being challenged, and a supporting reference — a DOI or PubMed identifier where possible — so a proposed change can be verified before it's acted on.

Editorial mailbox: editors@peptideslongisland.com

What this guide cannot do

So no message goes unanswered for the wrong reason: Peptides Long Island is a literature guide, not a clinical service, and cannot advise on human use of any peptide discussed here, suggest a dose or schedule for any individual, evaluate whether a cited finding applies to a specific person's situation, or help locate, source, or recommend a supplier for any compound. Semaglutide is a prescription medicine available only through licensed providers; retatrutide is investigational and available only within clinical trials; MOTS-c is not intended for human use. Readers seeking medical guidance should consult a licensed clinician. Responses to editorial correspondence are not guaranteed and may be delayed.